ArticleJournal of diabetes investigation2026
Impact of system updates for sensor-augmented pump therapy on glycemic management in Japanese individuals with type 1 diabetes (SAP-J T1D study).
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionSensor-augmented pump (SAP) therapy has evolved sequentially, but long-term clinical evidence supporting these advances has remained limited. We here evaluated the impact of updates to SAP therapy on glycemic outcomes in individuals with type 1 diabetes.
methodsThis retrospective observational study (SAP-J T1D) included Japanese individuals with type 1 diabetes receiving SAP therapy. Treatment efficacy of the MiniMed 620G, 640G, and 770G systems (Medtronic) was evaluated at three predefined time points: baseline (before the switch from 620G to 640G), before the switch from 640G to 770G, and 1 year after the switch to 770G. The primary outcome was the change in time in range (TIR) for continuous glucose monitoring from baseline to 1 year after the transition to the MiniMed 770G system.
resultsA total of 47 participants were included in the analysis. The median age was 45 years (interquartile range, 33-56 years), and the median body mass index was 22.3 kg/m
conclusionsSequential updates in SAP therapy were associated with stepwise improvements in glycemic management, reflecting the distinct functional characteristics of each system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.